Effectiveness and safety of olokizumab and levilimab in patients with COVID-19 in 2022: a cohort study

A single-center observational cohort study of the use of levilimab and olokizumab in patients with COVID-19 was conducted. Purpose was to evaluate the effectiveness and safety of olokizumab and levilimab in the infectious diseases hospital of the Volgograd region in 2022. Materials and methods: We analyzed 182 medical records of patients who were prescribed genetically engineered biological drugs in 2022. Long-term results of the use of drugs and disease outcomes after discharge or transfer to another medical fascility were assessed using the federal register of people with COVID-19. Results: There were no significant differences in the effectiveness of levilimab and olokizumab. The chance of detecting signs of bacterial infection/sepsis was significantly higher by 2.7 times in patients receiving levilimab compared with olokizumab (OR=2.7, 95 % CI 1.43-5.17).